Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Sara Fazi
Programmed Death Ligand 1 Expression in Prostate Cancer Cells Is Associated With Deep Changes of the Tumor Inflammatory Infiltrate Composition
Urologic Oncology: Seminars and Original Investigations
Oncology
Urology
Breast and Bone: A Story of Hidden Similarities
Chronicles of Oncology
Related publications
Programmed Death-Ligand 1 Expression and Its Correlation With Clinicopathological Parameters in Gallbladder Cancer
Journal of Pathology and Translational Medicine
Forensic Medicine
Pathology
Histology
Catching Up With Solid Tumor Oncology: What Is the Evidence for a Prognostic Role of Programmed Cell Death-Ligand 1/Programmed Cell Death-1 Expression in B-Cell Lymphomas?
Haematologica
Hematology
Erratum: Erratum: Expression of Programmed Death Ligand-1 on Tumor Cells Varies Pre and Post Chemotherapy in Non-Small Cell Lung Cancer
Scientific Reports
Multidisciplinary
P2.04-01 Associations Histological Subtype of Lung Adenocarcinoma and Programmed Death Ligand 1 (PD-L1) Expression in Tumor Cells.
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Programmed Death Ligand 1 (PD-L1) Expression in Primary Angiosarcoma
Journal of Cancer
Oncology
JCSE01.14 Effects of Neoadjuvant Chemotherapy on the Expression of Programmed Death Ligand-1 and Tumor Infiltrating Lymphocytes in Lung Cancer Tissues
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
MicroRNAs Aid the Assessment of Programmed Death Ligand�1 Expression in Patients With Non‑small Cell Lung Cancer
Oncology Letters
Cancer Research
Oncology
Clinicopathological Significance and Prognostic Implication of Programmed Death-1 Ligand 2 Expression in Colorectal Cancer
International Journal of Biological Markers
Oncology
Cancer Research
Clinical Biochemistry
Forensic Medicine
Medicine
Pathology
The Prognostic Role of Immune Checkpoint Markers Programmed Cell Death Protein 1 (PD-1) and Programmed Death Ligand 1 (PD-L1) in a Large, Multicenter Prostate Cancer Cohort
Oncotarget
Oncology